Literature DB >> 11979385

Evaluation of assays available to measure free testosterone.

John E Morley1, Ping Patrick, H M Perry.   

Abstract

This study compared the results of various testosterone assays in a cross-sectional study of 50 male subjects age 28 to 90 years. The purpose of the study was to determine the relationship of the various testosterone assays to one another. In addition, we determined week-to-week variability in testosterone and bioavailable testosterone in 16 subjects. The following assays were undertaken: total testosterone (T), free testosterone by equilibrium dialysis (FT(D)), bioavailable testosterone (BT), free testosterone by ultracentrifugation (FT(U)), and direct estimation of serum free T by an analog ligand radioimmunoassay (FT(A)). In addition, using total T and sex hormone-binding globulin (SHBG), we calculated the free androgen index (FAI = T/SHBG) and the free testosterone index (FTI) using the method of Vermeulen. In a second study, we measured the week-to-week variation in T and BT in a group of older males. Lastly, we demonstrated excellent stability of serum stored at -70 degrees C for up to 7 years for T and BT. Correlations of the various assays to increasing age were significant for all assays except total T (r = -.126). The best correlation was found with BT (r = -.744, P <.001). All measures were statistically significantly correlated with FT. The best correlations were FTI (r =.807, P <.007) and BT (r =.670, P <.001). If T was used to classify hypogonadism in comparison to BT, it resulted in misclassification in 42% of cases. In addition, we demonstrated a marked week-to-week variability in T and BT in older men with the T and BT being in the eugonadal range some weeks and hypogonadal on other occasions. This occurred in 8 of 16 men for T and 10 of 16 men for BT. Based on these data, we suggest that the FTI or BT are the most practical methods to determine hypogonadism. There is a need for increased awareness that marked week-to-week variability within a single individual can occur for measurements of both T and BT. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11979385     DOI: 10.1053/meta.2002.31975

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  37 in total

Review 1.  [Testosterone deficiency and the problem of normal values].

Authors:  H M Behre
Journal:  Urologe A       Date:  2004-09       Impact factor: 0.639

Review 2.  The endocrine pharmacology of testosterone therapy in men.

Authors:  Michael Oettel
Journal:  Naturwissenschaften       Date:  2004-01-28

3.  Androgen insufficiency in ageing men: how is it defined and should it be treated?

Authors:  Penelope Coates
Journal:  Clin Biochem Rev       Date:  2005-02

Review 4.  Andropause: is the emperor wearing any clothes?

Authors:  S H Tariq; M T Haren; M J Kim; J E Morley
Journal:  Rev Endocr Metab Disord       Date:  2005-05       Impact factor: 6.514

Review 5.  Frailty and hormones.

Authors:  John E Morley; Moon Jong Kim; Matthew T Haren
Journal:  Rev Endocr Metab Disord       Date:  2005-05       Impact factor: 6.514

Review 6.  Sarcopenia: diagnosis and treatment.

Authors:  J E Morley
Journal:  J Nutr Health Aging       Date:  2008 Aug-Sep       Impact factor: 4.075

7.  Association between endogenous sex steroid hormones and inflammatory biomarkers in US men.

Authors:  K K Tsilidis; S Rohrmann; K A McGlynn; S J Nyante; D S Lopez; G Bradwin; M Feinleib; C E Joshu; N Kanarek; W G Nelson; E Selvin; E A Platz
Journal:  Andrology       Date:  2013-09-30       Impact factor: 3.842

8.  Circulating total testosterone and PSA concentrations in a nationally representative sample of men without a diagnosis of prostate cancer.

Authors:  Sarah B Peskoe; Corinne E Joshu; Sabine Rohrmann; Katherine A McGlynn; Sarah J Nyante; Gary Bradwin; Adrian S Dobs; Norma Kanarek; William G Nelson; Elizabeth A Platz
Journal:  Prostate       Date:  2015-04-28       Impact factor: 4.104

9.  GH release after GHRH plus arginine administration in obese and overweight women with polycystic ovary syndrome.

Authors:  F Orio; S Palomba; A Colao; T Russo; C Dentico; L Tauchmanovà; S Savastano; C Nappi; C Sultan; F Zullo; G Lombardi
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

10.  The natural history of symptomatic androgen deficiency in men: onset, progression, and spontaneous remission.

Authors:  Thomas G Travison; Rebecca Shackelton; Andre B Araujo; Susan A Hall; Rachel E Williams; Richard V Clark; Amy B O'Donnell; John B McKinlay
Journal:  J Am Geriatr Soc       Date:  2008-05       Impact factor: 5.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.